戻る Agenda
The Development of Novel Digital Endpoints
Session Chair(s)
Michelle Crouthamel, PHD
Head, Digital Science
AbbVie, United States
This session will be used to present two examples of novel digital endpoint development with live chat and Q&A discussion to follow.
Learning Objective : Discuss the novel digital development framework through industry examples; Identify the concept of interest, the context of use, and the design of validation will be included.
Speaker(s)
Itching for Feedback: Framework for Qualifying Novel Digital Outcomes
Robert Mather, PHD
Pfizer Inc, United States
Executive Director, Early Clinical Development
The Development of Novel Digital Endpoints
Rinol Alaj, MBA
Regeneron Pharmaceuticals, United States
Director, Clinical Outcomes - Assessments and Innovation
The Development of Novel Digital Endpoints
Sara Hamon, PHD
Regeneron, United States
Director, Precision Medicine Quantitative Translational Sciences